Compare Recursion Pharmaceuticals Inc (RXRX) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SkyWest Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while SkyWest Inc trades at $95.26 (market cap $3.94B). The key difference: SkyWest Inc is far larger — about 2.6× Recursion Pharmaceuticals Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SKYW | |
|---|---|---|
Market Cap | $1.53B | $3.94B |
Sector | Health | Technology |
52-Week High | $6.79 | $123.72 |
52-Week Low | $2.84 | $78.40 |
Enterprise Value | $946.50M | $5.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
SkyWest (SKYW) trades at $99.34, up 2.17% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 9.52 and net income margin of 10.42%. Recent earnings beat expectations in Q1 2026, and analyst consensus is a buy with a $109.33 price target. The company announced a new president and COO in July 2026, signaling operational focus amid industry fuel cost pressures.
The outlook is positive given undervaluation and earnings momentum, but risks include elevated jet fuel expenses impacting airline profitability. Investor sentiment is supported by institutional buying and lack of sell ratings, though macroeconomic headwinds remain a key watchpoint for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
